CRISPR as a research tool in cancer and regenerative medicine
May 25, 2023 @ 08:00 – May 26, 2023 @ 17:00 CEST
This two-day event will bring together leading international experts in the field of CRISPR technology and CRISPR applications in basic research in cancer and regenerative medicine. Attendees will have the opportunity to gain a deeper understanding of the potential and limitations of CRISPR as a research tool, both in precision genome engineering and in massively parallel, functional genomics applications and unbiased screens.
There will be a poster session, and short talks will be chosen from submitted abstracts. This event will provide a valuable opportunity for students, researchers, educators, and industry professionals to learn about the latest developments and applications of this exciting and rapidly advancing field. PhD students are encouraged to submit a poster abstract to obtain educational credits towards their PhD. Come join us and learn how CRISPR can accelerate YOUR research!
The registration fee of 1,000 SEK (excl. VAT) includes access to the conference, lunches and coffee on 25-26 May 2023, as well as snacks and drinks at the poster session on May 25. According to Swedish and EU legislation 25% VAT will be added to the registration fee before payment.
|Expanding the CRISPR screening toolbox with Cas12a, base editors, and more|
John Doench, Broad MIT
|Better genome editing by listening to the cells|
Jacob Corn, ETH Zurich
|Fine-tuning of transcription factor expression dosage uncovers non-linear effects in regulatory networks|
Tuuli Lappalainen, KTH and New York Genome Center
|Uncovering key resistance mechanisms to cancer immunotherapy|
Yumeng Mao, Uppsala University
|Harnessing the CRISPR toolbox to engineer biology|
Randall J. Platt, ETH Zurich
|Target discovery – arrayed & pooled CRISPR screening to drive drug discovery|
Douglas Ross-Thriepland, AstraZeneca & CRUK Functional Genomics Centre
|New frontiers in pooled CRISPR screens|
Neville Sanjana, New York Genome Center
|CRISPR discovery platforms for human T cell therapies|
Eric Shifrut, Tel Aviv University